Cover Image


Rx-to-OTC Switch Pipelines USA: Competitive Assessment

出版商 Kline & Company, Inc. 商品編碼 353967
出版日期 內容資訊 英文 433 Pages
商品交期: 最快1-2個工作天內
Back to Top
美國的處方藥改列成藥醫藥品的開發平台:競爭分析 Rx-to-OTC Switch Pipelines USA: Competitive Assessment
出版日期: 2015年05月31日 內容資訊: 英文 433 Pages




  • 主要趨勢、模式轉移
  • 處方藥改列成藥醫藥品的法規標準
  • 近幾年的轉用
  • 對處方藥改列成藥醫藥品管理的組織結構
  • 臨床研究相關考察
  • 轉用的預測
  • 總論


  • 調查對象企業
    • Actavis
    • Astellas Pharma Inc.
    • AstraZeneca
    • Bayer Group
    • Boehringer-Ingelheim
    • Bristol-Myers Squibb
    • Chiesi USA
    • Galderma Laboratories
    • GlaxoSmithKline/Novartis
    • Johnson & Johnson
    • Meda Pharmaceuticals
    • Merck
    • Perrigo
    • Pfizer
    • Ranbaxy (Sun Pharmaceuticals)
    • Roche
    • Sanofi
    • Sunovion
    • 武田藥品工業
    • Teva
    • Valeant Pharmaceuticals
  • 調查內容
    • 現狀
    • 處方藥市場及OTC市場比較分析
    • 法律規章上的課題
      • 專利的失效
      • 安全性、有效性
      • 非處方醫藥品的潛在適應症
    • 轉用的可能性和時機
    • 銷售額預測
    • 來自品牌藥、自有品牌藥的競爭上的反應
  • 轉用藥物候補的類別
    • 粉刺
    • 過敏
    • 抗真菌
    • 前列腺肥大症 (BPH)
    • 膽固醇
    • 消化
    • 濕疹
    • 勃起功能障礙
    • 失禁
    • 大腸躁鬱症 (IBS)
    • 偏頭痛
    • 口服避孕藥
    • 骨質疏鬆症
    • 皮疹
    • 睡眠補助

Regional Coverage: United States


This report provides subscribers with a comprehensive, objective assessment of Rx-to-OTC switch pipelines by company in the United States. This analysis includes assessments of prescription-only pharmaceutical companies, as well as pharmaceutical companies with both OTC and prescription units. The report provides details on recently approved switches and forecasts of future switches by company. Included in the forecasts will be future switches in existing OTC categories and projected switches that would create new OTC categories.

This report helps subscribers to:

  • Assess Rx-to-OTC Switch forecasts by company
  • Analyze regulatory and retail paradigm shifts and implications for future switches
  • Cast a wide-net analysis for uncovering potential licensing opportunities
  • Benchmark one company's future switch potential against competitors


Rx-to-OTC Switch Pipelines USA: Competitive Assessment is the 11th edition in Kline's long running series of reports on Rx-to-OTC switch and seeks to examine future switch pipelines of OTC and prescription pharmaceutical companies. This report examines recent and future Rx-to-OTC switches by company in the United States. Each company's switch pipeline will be analyzed on a case-by-case basis, and the forecast time horizon may differ for each.

For each company and drug class, this report will provide:

  • Prescription drug sales for 2013 and 2014
  • OTC sales for 2013 and 2014 (where applicable)
  • Assessment of market dynamics including patent expirations, generic competition, advertising and promotions, and regulatory issues
  • Likelihood and timing of switches
  • Likely OTC claims/indications
  • Sales forecasts through 2019 or 2020; however, this may vary depending on various variables and are noted as such

Key Benefits

Rx-to-OTC Switch Pipelines USA: Competitive Assessment is an extensive industry resource used by sales, marketing, and business development executives in the pharmaceutical industry for competitive analysis, market investigation, acquisition screening, business planning, and strategic purposes. The report provides a comprehensive, objective assessment of Rx-to- OTC switch pipelines by company in the United States, examines key issues and implications that switches can have on the existing OTC market, and identifies opportunities for future growth from switches. Accurately predicting Rx-to-OTC switches and assessing their competitive impact is crucial for maximizing business opportunities, minimizing threats, and successfully constructing long term strategic plans. Specifically, the report provides subscribers with the following key deliverables:

  • Up-to-date primary research on switches conducted with knowledgeable industry participants
  • An objective perspective on future switches by company
  • Ability to cast wide net and uncover potential licensing opportunities
  • Realistic assessment of paradigm shifts and future implications
  • Identification of future switches by company, by identifying categories with high likelihood of switch, with what timing, and forecasting sales potential
  • A tool to use to benchmark your business against those of competitors
  • Access to Kline's proprietary and interactive FutureView forecasting model

Table of Contents


Executive Summary

An executive briefing including the assessment of:

  • Key trends and paradigm shifts
  • Regulatory criteria for Rx-to-OTC switch
  • Recent switches
  • Corporate structures for Rx-to-OTC switch management
  • Clinical study considerations
  • Switch forecasts
  • Conclusion

Switch Pipelines by Company

Assessment of companies shown in Table 1 including assessments of future switches in existing OTC categories and those that may create new OTC categories, including overview of the condition, comparative analysis of prescription and OTC markets (where applicable), regulatory issues including patent expiration data, safety/ efficacy, potential nonprescription indications and claims, likelihood of switch and expected timing, sales forecasts, expected competitive response from both branded and private-label products. Categories with potential switch candidates are shown in Table 2.

Back to Top